120 related articles for article (PubMed ID: 12872391)
21. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
23. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
24. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
25. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
[TBL] [Abstract][Full Text] [Related]
26. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
Yao G; Cui Z; Wang B; Yao J; Zeng M
Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
[TBL] [Abstract][Full Text] [Related]
27. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
[TBL] [Abstract][Full Text] [Related]
28. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
Feng B; Wei L; Chen M; Wang L
Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
[TBL] [Abstract][Full Text] [Related]
29. Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B.
Kim DY; Ahn SH; Lee HW; Park JY; Kim SU; Paik YH; Lee KS; Han KH; Chon CY
Intervirology; 2008; 51(4):293-8. PubMed ID: 19001828
[TBL] [Abstract][Full Text] [Related]
30. [Study of xiaozhang recipe combined with lamivudine in treatment of 84 chronic viral hepatitis B patients with compensated liver cirrhosis].
Zhou ZH; Li M; Huang LY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Sep; 31(9):1220-3. PubMed ID: 22013800
[TBL] [Abstract][Full Text] [Related]
31. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
32. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
Yeh CT; Chien RN; Chu CM; Liaw YF
Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
[TBL] [Abstract][Full Text] [Related]
33. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
Tipples GA; Ma MM; Fischer KP; Bain VG; Kneteman NM; Tyrrell DL
Hepatology; 1996 Sep; 24(3):714-7. PubMed ID: 8781348
[TBL] [Abstract][Full Text] [Related]
34. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
[TBL] [Abstract][Full Text] [Related]
35. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
36. [A study on the treatment of chronic hepatitis B with YMDD mutation].
Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
[TBL] [Abstract][Full Text] [Related]
37. [Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B].
Yan MH; Zhang C; Ling Q; Zhou RF
Zhonghua Gan Zang Bing Za Zhi; 2003 Jul; 11(7):430-1. PubMed ID: 12890351
[No Abstract] [Full Text] [Related]
38. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
39. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
[TBL] [Abstract][Full Text] [Related]
40. [Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
Chang YJ; Yim JY; Cho NY; Choi CW; Baek SJ; Ahn SH; Choi DW; Kwon YD; Kim SS; Kwon OS; Kim JH; Yeon JE; Song JW; Byun KS; Lee CH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):397-404. PubMed ID: 12506244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]